Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06347068 · ClinicalTrials.gov registry record · Phase 1

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

A Phase 1 study of Breast Cancer and Triple Negative Breast Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
42
Enrollment target
1
Study location

NCT06347068 is a Phase 1 study of Breast Cancer and Triple Negative Breast Cancer that is actively recruiting participants, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 42 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06347068, a Phase 1 study of Breast Cancer and Triple Negative Breast Cancer, is actively recruiting participants, sponsored by UNC Lineberger Comprehensive Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
42 participants
Enrollment target
1
Study location

Study Summary

This phase 1, single-center, open-label study explores the safety of escalating doses of chimeric antigen receptor T cells (CAR-T) cells in subjects with relapsed/refractory triple-negative breast cancer (TNBC).

Conditions Studied

Breast Cancer Triple Negative Breast Cancer Relapse Resistant Cancer

Interventions

  • DRUG fludarabine
  • DRUG cyclophosphamide
  • BIOLOGICAL iC9-CAR.B7-H3 T Cell Therapy

Study Locations (1)

North Carolina

  • University of North Carolina - Chapel Hill

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2024-06-27
Est. Completion 2028-05
Phase Phase 1

Sponsor

UNC Lineberger Comprehensive Cancer Center

366 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06347068

The ClinicalTrials.gov registry entry for NCT06347068 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which fludarabine is the first listed.

NCT06347068 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT06347068 about?

NCT06347068 is a clinical study titled "Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells". This phase 1, single-center, open-label study explores the safety of escalating doses of chimeric antigen receptor T cells (CAR-T) cells in subjects with relapsed/refractory triple-negative breast cancer (TNBC).

What is the current status of trial NCT06347068?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2024-06-27. Estimated completion is 2028-05.

What conditions does trial NCT06347068 study?

This clinical trial studies the following conditions: Breast Cancer, Triple Negative Breast Cancer, Relapse, Resistant Cancer.

What interventions are being tested in trial NCT06347068?

The interventions under investigation include: fludarabine (DRUG), cyclophosphamide (DRUG), iC9-CAR.B7-H3 T Cell Therapy (BIOLOGICAL).

Who is sponsoring clinical trial NCT06347068?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06347068 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Triple Negative Breast Cancer

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.